Clinical focus Target early-stage collaboration and licensing discussions around TGF-β signaling disorders, with emphasis on rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, aligning partnerships with Keros’ lead protein therapeutics portfolio.

Strategic partnerships Leverage frequent participation in major healthcare conferences (e.g., Goldman Sachs Global Healthcare Conference) to initiate introductions with potential pharma partners, contract research organizations, and academic collaborators to accelerate clinical development and co-development opportunities.

Funding readiness Position Keros as an active clinical-stage partner with strong backing (funding of ~$380M) to attract strategic investments, milestone-based deals, and potential co-funding arrangements for late-stage trials and commercialization efforts.

Talent and governance Engage potential advisory and board-level experts and expand governance with new director appointments to enhance credibility with large biotech and pharma collaborators seeking seasoned oversight for translational programs.

Technology enablement Highlight cloud-based infrastructure and data collaboration capabilities (AWS, Azure, OneDrive, DocuSign, Zscaler) as enablers for secure data sharing, centralized trial management, and scalable partner ecosystems to streamline joint development programs.